T cell repertoire changes predictive of anti-CTLA-4 cancer immunotherapy outcome revealed
A study using Sequenta's LymphoSIGHT platform reveals that patients with longer survival have lower numbers of T cell clones that decrease in frequency after treatment. This association holds for both prostate cancer and melanoma patients, suggesting that immune repertoire sequencing could predict clinical benefit of immunotherapies.